Capital Fund Six of Brandon raked in over A$439 million in closings.
Brandon Capital Raises Record A$439 Million for Biomedical Investments
Brandon Capital, a leading life sciences venture capital firm in Australasia, has reached a significant milestone with the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6). The fund, which focuses on investing in emerging biomedical technologies, has raised a record-breaking A$439 million, making it the firm's largest fund to date.
The BB6 fund aims to translate scientific discoveries into high-growth companies dedicated to improving human health. Notable investments made by BB6 include AdvanCell, PolyActiva, Myricx Bio, and CatalYm, all of which are working on innovative technologies in the fields of radiopharmaceuticals, glaucoma implant development, antibody-drug conjugates, and oncology-focused therapeutics, respectively.
Key partners and investors in this fund are established LPs like HESTA, Hostplus, CSL, and QIC, along with new investors such as the Western Australia Government and the National Reconstruction Fund Corporation (NRFC). The NRFC's investment in BB6 is aimed at attracting talent and capital to build local commercialization capabilities.
David Gall, CEO of NRFC, emphasizes the importance of early and considered investments in the biomedical sector to foster local commercialization capabilities and secure medical science jobs and industries in Australia for the future. The NRFC's investment strategy prioritizes making early investments in the biomedical sector to ensure the existence of medical science jobs and industries in Australia in the future.
Brandon Capital's commitment is to exceed its investors' expectations through its biomedical investments. The firm contributes significantly to the manufacturing sector in Australia while fostering global collaboration and enhancing Australia's research capabilities. Brandon Capital supports over 30 companies in Australia and is responsible for creating more than 270 skilled jobs in the country.
Recent successes of Brandon Capital include FDA approvals for therapies from George Medicines and EBR Systems, as well as Q-Sera's approval in Japan. However, no new information was provided about these successes, investments, companies supported, jobs created, or contributions to the manufacturing sector or research capabilities in Australia in the context of the BB6 fund.
Brandon Capital remains committed to advancing breakthrough biomedical innovations through scientific rigor and disciplined capital allocation. The BB6 fund is headquartered in Melbourne and builds on Brandon Capital’s track record of raising over A$1 billion across previous funds.
Read also:
- Rapid Construction of Rajasthan's 435 Megawatt Solar Power Plant in Eight Months Reduces Carbon Dioxide Emissions by Over 700,000 Tons
- Plastic apparel shipments from the EU to Kenya reach 37 million units, revels fresh data report
- "New Maxxi-charge storage proves effective in replacing entire rooftop systems"
- Exporo to Boost Investment in Socially Responsible Projects
